DefinitionBy Mayo Clinic staff
Cerebral palsy is a disorder of movement, muscle tone or posture that is caused by injury or abnormal development in the immature brain, most often before birth.
Signs and symptoms appear during infancy or preschool years. In general, cerebral palsy causes impaired movement associated with exaggerated reflexes or rigidity of the limbs and trunk, abnormal posture, involuntary movements, unsteadiness of walking, or some combination of these. The effect of cerebral palsy on functional abilities varies greatly.
People with cerebral palsy often have other conditions related to developmental brain abnormalities, such as intellectual disabilities, vision and hearing problems, or seizures. A broad spectrum of treatments may help minimize the effect of cerebral palsy and improve a person's functional abilities.
- Cerebral palsy: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/cerebral_palsy/detail_cerebral_palsy.htm. Accessed Sept. 27, 2010.
- Evaluating and diagnosing the child with cerebral palsy. American Academy of Neurology. http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.view&guideline=124. Accessed Sept. 27, 2010.
- Cerebral palsy. American Academy of Pediatrics. http://www.healthychildren.org/English/health-issues/conditions/developmental-disabilities/Pages/Cerebral-Palsy.aspx. Accessed Sept. 28, 2010.
- Krigger KW. Cerebral palsy: An overview. American Family Physician. 2006;73:91.
- Ashwal S, et al. Practice parameter: Diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004;62:851.
- Cerebral palsy: Drug treatments for spasticity in children and adolescents. American Academy of Neurology. http://www.aan.com/practice/guideline/index.cfm?fuseaction=home.view&guideline=389. Accessed Sept. 27, 2010.
- Delgado MR, et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74:336.
- Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm. Accessed Sept. 30, 2010.
- Patterson MC (expert opinion). Mayo Clinic, Rochester, Minn. Nov. 9, 2010.